Anja Roos

Anja Roos

Auto-generated profile, based on publicly available information

Anja Roos

Department of Clinical Chemistry, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
ARAnja Roos
Anja Roos
MRMaria Pia Rastaldi
Maria Pia Rastaldi
NCNovella Calvaresi
Novella Calvaresi
BOBeatrijs D. Oortwijn
Beatrijs D. Oortwijn
NSNicole Schlagwein
Nicole Schlagwein
MDMohamed R. Daha
Mohamed R. Daha
IgA nephropathy (IgAN) is characterized by glomerular co-deposition of IgA and complement components. Earlier studies showed that IgA activates the alternative pathway of complement, whereas more recent data also indicate activation of the lectin pathway. The lectin pathway can be activated by binding of mannose-binding lectin (MBL) and ficolins to carbohydrate ligands, followed by activation of MBL-associated serine proteases and C4. This study examined the potential role of the lectin pathway in IgAN. Renal biopsies of patients with IgAN (n = 60) showed mesangial deposition of IgA1 but not IgA2. Glomerular deposition of MBL was observed in 15 (25%) of 60 cases with IgAN and showed a mesangial pattern. All MBL-positive case, but none of the MBL-negative cases showed glomerular co-deposition of L-ficolin, MBL-associated serine proteases, and C4d. Glomerular deposition of MBL and L-ficolin was associated with more pronounced histologic damage, as evidenced by increased mesangial proliferation, extracapillary proliferation, glomerular sclerosis, and interstitial infiltration, as well as with significantly more proteinuria. Patients who had IgAN with or without glomerular MBL deposition did not show significant differences in serum levels of MBL, L-ficolin, or IgA or in the size distribution of circulating IgA. Furthermore, in vitro experiments showed clear binding of MBL to polymeric but not monomeric patient IgA, without a significant difference between both groups. Together, these findings strongly point to a role for the lectin pathway of complement in glomerular complement activation in IgAN and suggest a contribution for both MBL and L-ficolin in the progression of the disease.

1 September 2001 in The Journal of Immunology
Verified
Journal Article
Closed access
ARAnja Roos
Anja Roos
LBLee H Bouwman
Lee H Bouwman
DGDaniëlLe J van Gijlswijk-Janssen
DaniëlLe J van Gijlswijk-Janssen
MFMaria C Faber-Krol
Maria C Faber-Krol
GSGregory L Stahl
Gregory L Stahl
MDMohamed R Daha
Mohamed R Daha
The recently identified lectin pathway of the complement system, initiated by binding of mannan-binding lectin (MBL) to its ligands, is a key component of innate immunity. MBL-deficient individuals show an increased susceptibility for infections, especially of the mucosal system. We examined whether IgA, an important mediator of mucosal immunity, activates the complement system via the lectin pathway. Our results indicate a dose-dependent binding of MBL to polymeric, but not monomeric IgA coated in microtiter plates. This interaction involves the carbohydrate recognition domain of MBL, because it was calcium dependent and inhibited by mannose and by mAb against this domain of MBL. Binding of MBL to IgA induces complement activation, as demonstrated by a dose-dependent deposition of C4 and C3 upon addition of a complement source. The MBL concentrations required for IgA-induced C4 and C3 activation are well below the normal MBL plasma concentrations. In line with these experiments, serum from individuals having mutations in the MBL gene showed significantly less activation of C4 by IgA and mannan than serum from wild-type individuals. We conclude that MBL binding to IgA results in complement activation, which is proposed to lead to a synergistic action of MBL and IgA in antimicrobial defense. Furthermore, our results may explain glomerular complement deposition in IgA nephropathy.

1 January 2003 in Molecular Immunology
Verified
Journal Article
Closed access
ARAnja Roos
Anja Roos
LBLee H. Bouwman
Lee H. Bouwman
JMJeric Munoz
Jeric Munoz
TZTahlita Zuiverloon
Tahlita Zuiverloon
MFMaria C. Faber-Krol
Maria C. Faber-Krol
MDMohamed R. Daha
Mohamed R. Daha

23 March 2004 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
ARAnja Roos
Anja Roos
WXWei Xu
Wei Xu
GCGiuseppe Castellano
Giuseppe Castellano
ANAlma J. Nauta
Alma J. Nauta
PGPeter Garred
Peter Garred
CKCees van Kooten
Cees van Kooten
Apoptotic cells can be recognized and taken up by both macrophages and dendritic cells. Phagocytosis of apoptotic cells generally leads to active suppression of cytokine production by professional phagocytes. This is different from the response towards cells that die by necrosis, which induce a pro‐inflammatory cytokine profile. Uptake of apoptotic cells involves a large number of receptors and opsonins, which bind to cellular ligands exposed during the various stages of apoptotic cell death. Among the opsonins of apoptotic cells, complement factors, including C1q, and complement‐activating members of the pentraxin family play an important role. This is indicated by in vitro phagocytosis studies and supported by the susceptibility to systemic autoimmunity of carriersof genetic deficiencies for early complement proteins. The present review summarizes the role of molecules of innate immunity in the handling of apoptotic cells by macrophages and dendritic cells. It is proposed that C1q and other opsonins prevent autoimmunity and maintain self‐tolerance by supporting the efficient clearance of apoptotic material, as well as by actively modulating phagocyte function.

1 February 2005 in Kidney International
Verified
Journal Article
Closed access
PDF file
ANAlma J. Nauta
Alma J. Nauta
SHSimone De Haij
Simone De Haij
BBBarbara Bottazzi
Barbara Bottazzi
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
MBMaria C. Borrias
Maria C. Borrias
ARAnja Roos
Anja Roos

15 December 2001 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ARAnja Roos
Anja Roos
ANAlma J. Nauta
Alma J. Nauta
DBDaniël Broers
Daniël Broers
MFMaria C. Faber-Krol
Maria C. Faber-Krol
LTLeendert A Trouw
Leendert A Trouw
MDMohamed R. Daha
Mohamed R. Daha
Undesired activation of the complement system is a major pathogenic factor contributing to various immune complex diseases and conditions such as hyperacute xenograft rejection. We aim for prevention of complement-mediated damage by specific inhibition of the classical complement pathway, thus not affecting the antimicrobial functions of the complement system via the alternative pathway and the lectin pathway. Therefore, 42 peptides previously selected from phage-displayed peptide libraries on basis of C1q binding were synthesized and examined for their ability to inhibit the function of C1q. From seven peptides that showed inhibition of C1q hemolytic activity but no inhibition of the alternative complement pathway, one peptide (2J) was selected and further studied. Peptide 2J inhibited the hemolytic activity of C1q from human, chimpanzee, rhesus monkey, rat, and mouse origin, all with a similar dose-response relationship (IC50 2–6 μM). Binding of C1q to peptide 2J involved the globular head domain of C1q. In line with this interaction, peptide 2J dose-dependently inhibited the binding of C1q to IgG and blocked activation of C4 and C3 and formation of C5b-9 induced via classical pathway activation, as assessed by ELISA. Furthermore, the peptide strongly inhibited the deposition of C4 and C3 on pig cells following their exposure to human xenoreactive Abs and complement. We conclude that peptide 2J is a promising reagent for the development of a therapeutic inhibitor of the earliest step of the classical complement pathway, i.e., the binding of C1q to its target.